Evangelista S, Cochet P, Bromet N, Criscuoli M, Maggi C A
Menarini Ricerche S.P.A., Firenze, Italy.
Drug Metab Dispos. 2000 Jun;28(6):643-7.
The aim of this study was to determine the plasma levels and the tissue distribution of otilonium bromide, measured as total radioactivity, after oral administration of 2 mg/kg of (14)C-labeled drug to rats. Radioactivity levels were very low in the plasma (ranging from 2.7 ng Eq/ml at 1.5 h to 0.6 ng Eq/ml at 24 h) as compared with those found in the gastrointestinal (GI) tract, indicating negligible systemic otilonium bromide absorption. Results from both quantitative radioluminography of whole body tissue distribution and radioassay of dissected parts of the GI tract carried out with liquid scintillation counting clearly demonstrate the presence of radioactive compounds in the walls of the GI tract at all sacrifice times. In the other tissues and organs examined, radioactivity was only found in trace amounts in the liver. The presence of radioactivity in the GI walls reflected the transit kinetics of drug-enriched contents. The radioactivity in large intestine walls was measurable at otilonium bromide concentrations in the range of micromole equivalents/kg, from 4 to 8 h after drug administration. Total body radioactivity recovery was 95, 101, 24, and 9% at 1.5, 4, 8, and 24 h, respectively. In conclusion, orally administered (14)C-otilonium bromide is poorly absorbed systemically, as indicated by the very low plasma radioactivity levels, but it is able to effectively penetrate into the large intestine walls, a recognized target for drugs oriented toward irritable bowel syndrome therapy.
本研究的目的是在给大鼠口服2mg/kg的(14)C标记药物后,测定以总放射性衡量的奥替溴铵的血浆水平和组织分布。与胃肠道(GI)中的放射性水平相比,血浆中的放射性水平非常低(1.5小时时为2.7ng Eq/ml,24小时时为0.6ng Eq/ml),这表明奥替溴铵的全身吸收可忽略不计。通过液体闪烁计数对全身组织分布进行的定量放射自显影和对胃肠道解剖部分进行的放射分析结果清楚地表明,在所有处死时间,胃肠道壁中均存在放射性化合物。在检查的其他组织和器官中,仅在肝脏中发现微量放射性。胃肠道壁中放射性的存在反映了富含药物的内容物的转运动力学。在给药后4至8小时,当奥替溴铵浓度在微摩尔当量/千克范围内时,大肠壁中的放射性是可测量的。在1.5、4、8和24小时时,全身放射性回收率分别为95%、101%、24%和9%。总之,如极低的血浆放射性水平所示,口服(14)C-奥替溴铵的全身吸收很差,但它能够有效地渗透到大肠壁中,大肠壁是针对肠易激综合征治疗的药物的公认靶点。